Optimizing HCV Management within a System of Care: A Focus on Utilizing the PCMH Model to Improve Screening, Treatment, and Outcomes

Optimizing HCV Management within a System of Care: A Focus on Utilizing the PCMH Model to Improve Screening, Treatment, and Outcomes

On-Demand Webcast
FACULTY

Mina Harkins, MBA, PCMH CCE
Former Assistant Vice President
Recognition Programs Policy and Resources
National Committee for Quality Assurance


Paul Pockros, MD

Director, Liver Disease Center
Scripps Clinic
Director of Clinical Research, Scripps
Translational Science Institute

INTENDED LEARNERS

This activity is intended for professionals devoted to transforming care through the medical home model of care, including physicians, allied health professionals, practice administrators, quality managers, and consultants.

LEARNING OBJECTIVES

After completing this activity, participants should be able to:

  • Describe the growing HCV epidemic in terms of shifting demographics, under-diagnosis, and under-treatment
  • Implement appropriate HCV screening practices for at-risk patient populations
  • Outline the latest information on DAAs, including pan-genotypic all-oral regimens promoting adherence and meeting the needs of a broader range of patients
ACTIVITY OVERVIEW

To be eligible for documentation of credit, participants must participate in the full activity, complete the 10-question post-test with a score of 70% or better, and complete the evaluation form. Participants who successfully complete the post-test and evaluation form online may immediately print their documentation of credit.

Participants who have successfully completed the live version of this activity are not eligible to receive credit for this enduring material.

Release Date: November 30, 2018
Expiration Date: November 30, 2019
Estimated time to complete: 45 minutes

For questions regarding this educational activity, please call 609-371-1137.

ACCREDITATION INFORMATION

In support of improving patient care, the National Committee for Quality Assurance (NCQA) is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE) and the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for the healthcare team.

CME

NCQA designates this enduring material for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE

This continuing nursing education activity awards .75 contact hours.

CPE

This activity is approved for .75 contact hours (.0075 CEU) of continuing pharmacy education (UAN JA0004597-0000-18-024-H04-P).

This educational activity is a knowledge-based activity.

Clinical Reviewer: Karla Thornton, MD, MPH, Professor, Division of Infectious Diseases, University of New Mexico Health Sciences Center, Associate Director, Project ECHO

Nurse Reviewer: Johann Chanin, Senior Consultant, Steadman Group, Denver, CO

PLANNING COMMITTEE

The planning committee comprises Johann Chanin, MSN, RN, PCMH CCE; Mina Harkins, MBA, PCMH CCE; Paul Pockros, MD; Karla Thornton, MD, MPH; Vashon Coehins, Jennifer D'Alessandro, and Bart Ecker, NCQA; and Kristin Ciszeski, Mary Johnson, Michael Kearney, Randy Robbin, and Susan Yarbrough, NACCME.

 

FINANCIAL DISCLOSURE AND CONFLICTS OF INTEREST

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty reported the following:

Ms. Chanin, Ms. Harkins, Dr. Thornton, and Dr. Pockros have disclosed no relevant financial relationships with any commercial interests.

Ms. Coehins, Ms. D'Alessandro, Mr. Ecker, Ms. Ciszeski, Ms. Johnson, Mr. Kearney, Mr. Robbin, and Ms. Yarbrough have disclosed no relevant financial relationships with any commercial interests.

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentations.

The faculty have disclosed no off label/unapproved uses of drugs and/or devices will be discussed in the presentations.

HARDWARE/SOFTWARE REQUIREMENTS

The evaluation is accessible after the activity via a PC (Windows 7 or newer) or Mac (Mac OS 10.6 or later) computer with current versions of the following browsers: Internet Explorer, Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.

PRIVACY POLICY

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. NACCME and our joint sponsors will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

NACCME maintains physical, electronic and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2018 by North American Center for Continuing Medical Education, LLC (NACCME). All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from NACCME. The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

GRANT SUPPORT

This educational activity is supported by an educational grant from Gilead Sciences, Inc.